JP6341486B2 - リポ多糖、ペプチドグリカン及び1,3−β−D−グルカンを検出するためのロブスター血球抽出物からの組成物 - Google Patents
リポ多糖、ペプチドグリカン及び1,3−β−D−グルカンを検出するためのロブスター血球抽出物からの組成物 Download PDFInfo
- Publication number
- JP6341486B2 JP6341486B2 JP2014549358A JP2014549358A JP6341486B2 JP 6341486 B2 JP6341486 B2 JP 6341486B2 JP 2014549358 A JP2014549358 A JP 2014549358A JP 2014549358 A JP2014549358 A JP 2014549358A JP 6341486 B2 JP6341486 B2 JP 6341486B2
- Authority
- JP
- Japan
- Prior art keywords
- detecting
- peptidoglycan
- glucan
- lobster
- lipopolysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002158 endotoxin Substances 0.000 title claims description 59
- 229920006008 lipopolysaccharide Polymers 0.000 title claims description 46
- 210000000601 blood cell Anatomy 0.000 title claims description 24
- 241000238565 lobster Species 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title claims description 20
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title claims description 13
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 title claims description 11
- 108010013639 Peptidoglycan Proteins 0.000 title claims description 11
- 229920002498 Beta-glucan Polymers 0.000 title claims description 10
- 239000000284 extract Substances 0.000 title claims description 6
- 230000000694 effects Effects 0.000 claims description 28
- 108060008724 Tyrosinase Proteins 0.000 claims description 25
- 102000003425 Tyrosinase Human genes 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 17
- 239000003146 anticoagulant agent Substances 0.000 claims description 15
- 229940127219 anticoagulant drug Drugs 0.000 claims description 15
- 210000000087 hemolymph Anatomy 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 230000035945 sensitivity Effects 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 102000035195 Peptidases Human genes 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 235000019833 protease Nutrition 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 8
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 7
- 238000006395 oxidase reaction Methods 0.000 claims description 7
- 239000012139 lysis buffer Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 230000035939 shock Effects 0.000 claims description 5
- 239000003593 chromogenic compound Substances 0.000 claims description 4
- 108010069727 pro-phenoloxidase Proteins 0.000 claims description 4
- 229940122344 Peptidase inhibitor Drugs 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 108010072676 prephenoloxidase-activating enzyme Proteins 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000238017 Astacoidea Species 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 239000000644 isotonic solution Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 108010036927 trypsin-like serine protease Proteins 0.000 claims description 2
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 14
- 239000000872 buffer Substances 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 9
- 241001529572 Chaceon affinis Species 0.000 description 8
- 241000239205 Merostomata Species 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 108010001062 polysaccharide-K Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- 239000012480 LAL reagent Substances 0.000 description 5
- 238000001641 gel filtration chromatography Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002510 pyrogen Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
- 241000238421 Arthropoda Species 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000239218 Limulus Species 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- KQJTXYQXRHCWKW-PJSBSAQXSA-N (4s)-4-[[(2s,3s)-2-benzamido-3-methylpentanoyl]amino]-5-[[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid;hydrochloride Chemical compound Cl.N([C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C1=CC=CC=C1 KQJTXYQXRHCWKW-PJSBSAQXSA-N 0.000 description 2
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 2
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000239219 Carcinoscorpius rotundicauda Species 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 241000239221 Tachypleus gigas Species 0.000 description 2
- 241000239224 Tachypleus tridentatus Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010031969 benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000003366 endpoint assay Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- -1 isophylline Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- DZAUWHJDUNRCTF-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(O)C(O)=C1 DZAUWHJDUNRCTF-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000239220 Limulus polyphemus Species 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241000238048 Panulirus argus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000254109 Tenebrio molitor Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000004423 amoeboid cell Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 108090001082 glucan-binding proteins Proteins 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20110243A CU24073B1 (es) | 2011-12-27 | 2011-12-27 | COMPOSICIÓN A PARTIR DE EXTRACTO DE HEMOCITOS DE LANGOSTA PARA LA DETECCIÓN DE LIPOPOLISACÁRIDOS, PEPTIDOGLICANOS Y 1,3-ß-D-GLUCANOS |
| CUCU-2011-0243 | 2011-12-27 | ||
| PCT/CU2012/000009 WO2013113296A1 (es) | 2011-12-27 | 2012-12-27 | COMPOSICIÓN A PARTIR DE EXTRACTO DE HEMOCITOS DE LANGOSTA PARA LA DETECCIÓN DE LIPOPOLISACÁRIDOS, PEPTIDOGLICANOS Y 1,3-β-ϋ-GLUCANOS. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506679A JP2015506679A (ja) | 2015-03-05 |
| JP6341486B2 true JP6341486B2 (ja) | 2018-06-13 |
Family
ID=47632642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014549358A Expired - Fee Related JP6341486B2 (ja) | 2011-12-27 | 2012-12-27 | リポ多糖、ペプチドグリカン及び1,3−β−D−グルカンを検出するためのロブスター血球抽出物からの組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10023899B2 (enExample) |
| EP (1) | EP2811031B8 (enExample) |
| JP (1) | JP6341486B2 (enExample) |
| BR (1) | BR112014016111B1 (enExample) |
| CA (1) | CA2861982C (enExample) |
| CO (1) | CO7101194A2 (enExample) |
| CU (1) | CU24073B1 (enExample) |
| ES (1) | ES2690565T3 (enExample) |
| IN (1) | IN2014DN05849A (enExample) |
| WO (1) | WO2013113296A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24750B1 (es) | 2020-11-19 | 2025-06-11 | Centro De Investig Y Desarrollo De Medicamentos Cidem | Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US497052A (en) | 1893-05-09 | Eyelid-lifter | ||
| US547984A (en) | 1895-10-15 | Cutter-cylinder | ||
| US3954663A (en) | 1972-12-18 | 1976-05-04 | Teikoku Horinine Mfg. Co. Ltd. | Process for the preparation of Limulina lysate |
| US4023802A (en) | 1974-10-02 | 1977-05-17 | Acushnet Company | Golf club wood |
| US4107077A (en) | 1975-07-14 | 1978-08-15 | Associates Of Cape Cod, Inc. | Limulus lysate of improved sensitivity and preparing the same |
| US4038029A (en) | 1976-01-20 | 1977-07-26 | Worthington Biochemical Corporation | Limulus lysate turbidity test for pyrogens |
| JPS5415797A (en) | 1977-06-14 | 1979-02-05 | Seikagaku Kogyo Co Ltd | Detection and measurement of toxin in cells |
| US4229541A (en) | 1978-10-06 | 1980-10-21 | Baxter Travenol Laboratories, Inc. | In vitro cultivation of horseshoe crab amebocytes |
| US4279774A (en) | 1979-11-13 | 1981-07-21 | Dynasciences Corporation | Method of removing lipid inhibitors from limulus amebocyte lysate |
| US4322217A (en) | 1980-06-27 | 1982-03-30 | Mallinckrodt, Inc. | Process for preparing Limulus lysate |
| US4510241A (en) | 1981-09-03 | 1985-04-09 | Mallinckrodt, Inc. | Peptide-type substrates useful in the quantitative determination of endotoxin |
| ATE188777T1 (de) | 1986-12-03 | 2000-01-15 | Wako Pure Chem Ind Ltd | Verfahren zum sammeln von insekten- körperflussigkeiten |
| JPH0715474B2 (ja) | 1988-02-27 | 1995-02-22 | 和光純薬工業株式会社 | エンドトキシンの測定法 |
| JPH0711523B2 (ja) | 1988-03-16 | 1995-02-08 | 和光純薬工業株式会社 | 試薬の調製方法 |
| CA1328074C (en) | 1988-09-01 | 1994-03-29 | Shigenori Tanaka | Horseshoe crab amebocyte lysate factor g inhibitor |
| US5082782A (en) | 1988-12-27 | 1992-01-21 | Worcester Polytechnic Institute | Production of horseshoe crab amebocytes in vitro |
| ATE148230T1 (de) | 1989-10-30 | 1997-02-15 | Biowhittaker Inc | Kinetische bestimmungsmethode für endotoxin unter verwendung von limulus-amoebocyten-lysat und chromogenem substrat |
| DE69129365T2 (de) | 1990-08-22 | 1998-10-08 | Seikagaku Kogyo K K Seikagaku | Testagens für endotoxin |
| JP3122454B2 (ja) | 1990-09-27 | 2001-01-09 | 生化学工業株式会社 | カブトガニ・アメボサイト・ライセートの調製法 |
| JP3429036B2 (ja) | 1993-09-30 | 2003-07-22 | 生化学工業株式会社 | エンドトキシンの特異的測定剤 |
| DE69430038T2 (de) | 1993-11-18 | 2002-10-24 | Wako Pure Chemical Industries, Ltd. | Verfahren zur Bestimmung der Aktivität des Prophenoloxidaseaktivierenden Enzyms und dessen Anwendung |
| US5716834A (en) | 1994-08-19 | 1998-02-10 | National University Of Singapore | Cloned factor C cDNA of the Singapore horseshoe crab, Carcinoscorpius rotundicauda and purification of factor C proenzyme |
| US6645724B1 (en) | 1997-09-19 | 2003-11-11 | National University Of Singapore | Assays for endotoxin |
| US6270982B1 (en) | 1997-10-09 | 2001-08-07 | Charles River Laboratories | Methods and compositions for the detection of bacterial endotoxins |
| EP0924220A3 (en) | 1997-12-16 | 2000-04-26 | Wako Pure Chemical Industries, Ltd. | Inhibitor of the activation of beta-glucan recognition protein |
| US5998389A (en) | 1998-05-20 | 1999-12-07 | Biowhitaker Technologies | Endotoxin-specific assay |
| JP3657913B2 (ja) | 2000-01-20 | 2005-06-08 | サムヤン ジェネックス コーポレイション | β−1、3−グルカン検出用組成物、その製造方法及びそれを利用したβ−1、3−グルカン検出用キット |
| JP2005500520A (ja) | 2001-06-28 | 2005-01-06 | ケンブレックス バイオ サイエンス ウォカーズビル インコーポレーティッド | エンドトキシンを検出するための方法および試薬 |
| WO2003083090A1 (en) | 2002-03-28 | 2003-10-09 | Council Of Scientific And Industrial Research | In vitro culture of amoebocytes from tachypleus gigas in leibovitz culture medium |
| US7598054B2 (en) | 2003-10-31 | 2009-10-06 | Immunetics, Inc. | Rapid peptidoglycan-based assay for detection of bacterial contamination of platelets |
| EP3190185A1 (en) | 2006-07-07 | 2017-07-12 | Seikagaku Corporation | Pro-clotting enzyme, and method for detection of endotoxin or (1-3)-beta-d-glucan using the same |
| EP2122632B1 (en) | 2006-12-22 | 2014-06-25 | Sidense Corp. | Dual function data register |
-
2011
- 2011-12-27 CU CU20110243A patent/CU24073B1/es active IP Right Grant
-
2012
- 2012-12-27 WO PCT/CU2012/000009 patent/WO2013113296A1/es not_active Ceased
- 2012-12-27 ES ES12821102.6T patent/ES2690565T3/es active Active
- 2012-12-27 US US14/368,697 patent/US10023899B2/en active Active
- 2012-12-27 IN IN5849DEN2014 patent/IN2014DN05849A/en unknown
- 2012-12-27 JP JP2014549358A patent/JP6341486B2/ja not_active Expired - Fee Related
- 2012-12-27 CA CA2861982A patent/CA2861982C/en active Active
- 2012-12-27 EP EP12821102.6A patent/EP2811031B8/en not_active Not-in-force
- 2012-12-27 BR BR112014016111-9A patent/BR112014016111B1/pt not_active IP Right Cessation
-
2014
- 2014-07-25 CO CO14162207A patent/CO7101194A2/es unknown
-
2018
- 2018-06-20 US US16/012,975 patent/US10844421B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2811031B8 (en) | 2018-12-26 |
| BR112014016111B1 (pt) | 2020-11-24 |
| CU20110243A7 (es) | 2013-08-29 |
| CA2861982A1 (en) | 2013-08-08 |
| ES2690565T3 (es) | 2018-11-21 |
| US20140356889A1 (en) | 2014-12-04 |
| BR112014016111A8 (pt) | 2020-10-27 |
| IN2014DN05849A (enExample) | 2015-05-22 |
| CO7101194A2 (es) | 2014-10-31 |
| EP2811031B1 (en) | 2018-07-11 |
| WO2013113296A1 (es) | 2013-08-08 |
| US10023899B2 (en) | 2018-07-17 |
| US20180340206A1 (en) | 2018-11-29 |
| BR112014016111A2 (pt) | 2018-05-22 |
| CA2861982C (en) | 2020-11-10 |
| US10844421B2 (en) | 2020-11-24 |
| JP2015506679A (ja) | 2015-03-05 |
| EP2811031A1 (en) | 2014-12-10 |
| CU24073B1 (es) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | β-l, 3 Glucan activation of crustacean hemocytes in vitro and in vivo | |
| Hernández-López et al. | Activation of the prophenoloxidase system of the brown shrimp Penaeus californiensis Holmes | |
| Faisal et al. | Evidence for the presence of protease inhibitors in eastern (Crassostrea virginica) and Pacific (Crassostrea gigas) oysters | |
| Margres et al. | Functional characterizations of venom phenotypes in the eastern diamondback rattlesnake (Crotalus adamanteus) and evidence for expression-driven divergence in toxic activities among populations | |
| Smith et al. | Cell cooperation during host defense in the solitary tunicate Ciona intestinalis (L) | |
| Castro et al. | Trichinella spiralis: peroxidase activity in isolated cells from the rat intestine | |
| Parrinello et al. | Phenoloxidases in ascidian hemocytes: characterization of the pro-phenoloxidase activating system | |
| Saul et al. | Prophenoloxidase activation in the hemolymph of Sarcophaga bullata larvae | |
| Armstrong et al. | The Limulus blood cell secretes α2-macroglobulin when activated | |
| Jiménez et al. | Physiological and immunological characterization of Caribbean spiny lobsters Panulirus argus naturally infected with Panulirus argus Virus 1 (PaV1) | |
| Hougie | Coagulation changes in healthy and sick Pacific salmon | |
| Miranpuri et al. | Morphology and cytochemistry of hemocytes and analysis of hemolymph from Melanoplus sanguinipes (Orthoptera: Acrididae) | |
| Thorson | The effect of extracts of the amphidial glands, excretory glands, and esophagus of adults of Ancylostoma caninum on the coagulation of dog's blood | |
| JP6341486B2 (ja) | リポ多糖、ペプチドグリカン及び1,3−β−D−グルカンを検出するためのロブスター血球抽出物からの組成物 | |
| Soderhall et al. | The effects of β1, 3-glucans on blood coagulation and amebocyte release in the horseshoe crab, Limulus polyphemus | |
| Galgani | Digestive proteolysis and digestive proteinases in deep sea crabs Geryon affinis and Chionoecetes japonicus. | |
| Li et al. | Preparation and antithrombotic activity identification of Perinereis aibuhitensis extract: A high temperature and wide pH range stable biological agent | |
| CA2397495C (en) | Composition for detecting beta-1,3-glucan, preparation method thereof and diagnostic kit detecting beta-1,3-glucan | |
| Asokan et al. | Functional analysis of plasma prophenoloxidase system in the marine mussel Perna viridis | |
| Su et al. | Annexin gene family in Spirometra mansoni (Cestoda: Diphyllobothriidae) and its phylogenetic pattern among Platyhelminthes of medical interest | |
| CN103789254A (zh) | 昆虫、昆虫血淋巴及其组装活性物和应用 | |
| Yoshino et al. | Aminopeptidase activity in the hemolymph and body tissues of the pulmonate gastropod Biomphalaria glabrata | |
| Cheng et al. | Identification and characterization of proteins with phenoloxidase-like activities in the sea urchin Strongylocentrotus nudus | |
| KR100471308B1 (ko) | 펩티도글리칸 검출용 조성물, 및 이를 이용한펩티도글리칸 검출키트 | |
| Denis et al. | Calcium dependent lectin in the serum of the marine crab Atergatis subdentatus (De Hann 1835) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150907 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160621 |
|
| A603 | Late request for extension of time limit during examination |
Free format text: JAPANESE INTERMEDIATE CODE: A603 Effective date: 20161101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170411 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170706 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170905 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171010 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180410 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180508 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6341486 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |